Protalix Biotherapeutics (PLX) P/E Ratio
P/E Ratio as of Jun 13, 2025: 35.48
Average38.02
Median37.74
Minimum35.48
Maximum40.95
35.48
Past Month-4.28 (10.76%)
The P/E ratio for Protalix Biotherapeutics (PLX) is 35.48 as of Jun 13, 2025. This represents a increase of 159.93% compared to its 12-month average P/E ratio of 13.65. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Protalix Biotherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protalix Biotherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protalix Biotherapeutics to industry peers.
Protalix Biotherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protalix Biotherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protalix Biotherapeutics to industry peers.
Protalix Biotherapeutics (PLX) P/E Ratio Insights
See Protalix Biotherapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Protalix Biotherapeutics (PLX)
Order type
Buy in
Order amount
Est. shares
0 shares
Protalix Biotherapeutics (PLX) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $1.58 | 37.62 |
| May 1, 2025 | $3.00 | 114.07 |
| Apr 1, 2025 | $2.54 | 96.58 |
| Mar 3, 2025 | $2.31 | -16.24 |
| Feb 3, 2025 | $2.42 | -17.02 |
| Jan 2, 2025 | $1.97 | -13.85 |
Protalix Biotherapeutics (PLX) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | 35.48 | -368.38% |
| 2024 | -13.22 | -130.38% |
| 2023 | 43.52 | -1,308.89% |
| 2022 | -3.60 | +101.12% |
| 2021 | -1.79 | -92.33% |
| 2020 | -23.33 | — |
FAQs About Protalix Biotherapeutics (PLX) P/E ratio
The latest P/E ratio of Protalix Biotherapeutics (PLX) is 35.48, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Protalix Biotherapeutics’s last 12-month average P/E ratio is 13.65, compared to its current P/E ratio of 35.48. This reflects a increase of 159.93%.
Protalix Biotherapeutics’s current P/E ratio of 35.48 is higher than its last 12-month average P/E of 13.65. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Protalix Biotherapeutics’s average P/E ratio over the last 3 years is 19.35. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Protalix Biotherapeutics’s average P/E ratio over the last 5 years is 7.39. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.